Visual Q&A model predicts survival in PSMA radiopharmaceutical therapy

Visual QA model integrating PSMA PET/SPECT and PSA predicted 24-mo survival in 110 mCRPC patients: accuracy 81.8% internally (95% CI 0.52-0.95) and 71.9% externally, AUC 0.75.

• Retrospective multicenter study across 2 institutions, 110 mCRPC patients treated with two PSMA radioligands.
• VQA outperformed state-of-the-art approaches and showed closest calibration to ground-truth survival distribution (log-rank P=0.76).
• External validation with [177Lu]Lu-PSMA-617 cohort after few-shot fine-tuning.

Automated summary

RadPigeon summaries are original and for information only. They are not clinical advice.